Coexistence of superficial pemphigus and psoriasis.
We describe a case of the coexistence of psoriasis and pemphigus erythematosus. The coexistence of these two diseases may be more than coincidental: the effects of one immune-mediated skin disease may influence the occurrence of another. Possible mechanisms include antigen modification, altered regulation of T-cell activity, and plasminogen activator abnormalities.
Panzarella
K
K
Department of Dermatology, Cleveland Clinic Foundation, Ohio 44195, USA.
Camisa
C
C
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016525:Antigenic Modulation; D001327:Autoimmune Diseases / Q000276:immunology; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use; D004890:Erythema; D005050:Etretinate / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010392:Pemphigus / Q000150:complications* / Q000276:immunology; D010960:Plasminogen Activators / Q000276:immunology; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011565:Psoriasis / Q000150:complications* / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D007641:Keratolytic Agents; D005050:Etretinate; D003622:Dapsone; D010960:Plasminogen Activators; D011241:Prednisone